Literature DB >> 8454878

Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys.

Y Yasutomi1, S Koenig, S S Haun, C K Stover, R K Jackson, P Conard, A J Conley, E A Emini, T R Fuerst, N L Letvin.   

Abstract

Because the transmission of HIV is likely to occur through cell-associated virus, an effective HIV vaccine should be capable of eliciting HIV-specific CTL. We have employed the simian immunodeficiency virus (SIV)/rhesus monkey model to explore the use of the attenuated tuberculosis bacillus, Calmette Guérin bacillus (BCG), as a vaccine vehicle to elicit AIDS virus-specific CTL. BCG was engineered to express SIVmac gag under the control of hsp70 regulatory sequences. Immunization with this rBCG-SIVmac gag elicited MHC class I-restricted, CD8+ SIVmac gag-specific CTL in rhesus monkeys. In fact, SIVmac gag-specific CTL could be cloned readily from peripheral blood lymphocytes of these immunized monkeys. These findings provide further evidence for the power of BCG as a vaccine vector and its continued exploration as a vehicle for eliciting HIV-specific immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454878

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses.

Authors:  I Méderlé; I Bourguin; D Ensergueix; E Badell; J Moniz-Peireira; B Gicquel; N Winter
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

3.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R L Glickman; J Q Yang; A Kaur; J T Dion; M J Mulligan; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.

Authors:  Mark J Cayabyab; Avi-Hai Hovav; Tsungda Hsu; Georgia R Krivulka; Michelle A Lifton; Darci A Gorgone; Glenn J Fennelly; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids.

Authors:  R Wang; D L Doolan; Y Charoenvit; R C Hedstrom; M J Gardner; P Hobart; J Tine; M Sedegah; V Fallarme; J B Sacci; M Kaur; D M Klinman; S L Hoffman; W R Weiss
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 6.  Lactic acid bacteria as vaccine delivery vehicles.

Authors:  J M Wells; K Robinson; L M Chamberlain; K M Schofield; R W Le Page
Journal:  Antonie Van Leeuwenhoek       Date:  1996-10       Impact factor: 2.271

7.  Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.

Authors:  Maximillian Rosario; John Fulkerson; Shamit Soneji; Joe Parker; Eung-Jun Im; Nicola Borthwick; Anne Bridgeman; Charles Bourne; Joan Joseph; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing glutathione S-transferase from Schistosoma haematobium.

Authors:  L Kremer; L Dupré; G Riveau; A Capron; C Locht
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  The construction of Schistosoma japonicum vaccine BCG-Sj26GST and its identification.

Authors:  Y Huangfu; B Zheng; J Cheng; J Liang; Z Feng
Journal:  J Tongji Med Univ       Date:  1999
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.